Department of Infectious Diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Internal Medicine Department, Tehran University of Medical Sciences, Tehran, Iran.
J Med Virol. 2020 Jul;92(7):915-918. doi: 10.1002/jmv.25839. Epub 2020 Apr 19.
An 80-year-old man with multiple comorbidities presented to the emergency department with tachypnea, tachycardia, fever, and critically low O saturation and definitive chest computerized tomography scan findings in favor of COVID-19 and positive PCR results in 48 hours. He received antiviral treatment plus recombinant human erythropoietin (rhEPO) due to his severe anemia. After 7 days of treatment, he was discharged with miraculous improvement in his symptoms and hemoglobin level. We concluded that rhEPO could attenuate respiratory distress syndrome and confront the severe acute respiratory syndrome coronavirus 2 virus through multiple mechanisms including cytokine modulation, antiapoptotic effects, leukocyte release from bone marrow, and iron redistribution away from the intracellular virus.
一位 80 岁的老年男性，合并多种基础疾病，因呼吸急促、心动过速、发热以及极低的血氧饱和度而到急诊就诊，胸部计算机断层扫描（CT）明确COVID-19 诊断，48 小时内聚合酶链反应（PCR）阳性。由于严重贫血，他接受了抗病毒治疗加重组人促红细胞生成素（rhEPO）治疗。治疗 7 天后，他出院，症状和血红蛋白水平均显著改善。我们得出结论，rhEPO 通过多种机制减轻呼吸窘迫综合征，并对抗严重急性呼吸综合征冠状病毒 2 型病毒，包括细胞因子调节、抗细胞凋亡作用、白细胞从骨髓释放以及铁从细胞内病毒重新分布。
